Relacorilant was employed in seven patients with ACTH-independent Cushing’s syndrome, including patients with MACS, and in the low-dose group (100–200 mg/d; n = 17), 5/12 patients (41.7%) with hypertension achieved a good response. This evidence concerns the gene POMC and Cushing syndrome due to macronodular adrenal hyperplasia.